You are here

painkillers

Pain points: Unsolved recruitment and trial design issues in pain clinical trials

Pain points: Unsolved recruitment and trial design issues in pain clinical trials

Clinical Trials Arena

clinical trials

Flag link:

Competing in These 3 Markets Could Send Eli Lilly Stock Soaring

Competing in These 3 Markets Could Send Eli Lilly Stock Soaring

Motley Fool

Alzheimer's disease

Flag link:

Artificial intelligence may influence whether you can get pain medication

Artificial intelligence may influence whether you can get pain medication

Medical Marketing and Media

artificial intelligence

Flag link:

Promising Vertex Pain Med Points to New Era for Analgesics

Promising Vertex Pain Med Points to New Era for Analgesics

BioSpace

Vertex Pharmaceuticals

post-surgical pain

Flag link:

Drug makers leave the pain behind

Drug makers leave the pain behind

EP Vantage

Ampio Pharmaceuticals

Eliem Therapeutics

Teva Pharamceutical

Vertex Pharmaceuticals

Flag link:

Late-stage pain pipeline refuses to swell

Late-stage pain pipeline refuses to swell

EP Vantage

Teva Pharmaceutical

Ampio Pharmaceuticals

Vertex Pharmaceuticals

Acadia Pharmaceuticals

Flag link:

Her husband died by suicide. She sued his pain doctors — a rare challenge over an opioid dose reduction

Her husband died by suicide. She sued his pain doctors — a rare challenge over an opioid dose reduction

Stat

Flag link:

Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel

Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel

Fierce Biotech

non-opioid pain treatments

University of Arizona

Flag link:

Vertex picks a horse in race for opioid painkiller replacement

Vertex picks a horse in race for opioid painkiller replacement

Fierce Biotech

Vertex Pharmaceuticals

clinical trials

non-opioid pain treatments

Flag link:

In highly unusual move, Pacira sues medical journal for libel over its non-opioid painkiller

In highly unusual move, Pacira sues medical journal for libel over its non-opioid painkiller

Endpoints

medical journals

non-opioid pain treatments

Flag link:

Trevena preps low-key launch, responsible marketing for long-awaited opioid Olinvyk

Trevena preps low-key launch, responsible marketing for long-awaited opioid Olinvyk

Fierce Pharma

Flag link:

Former Indivior CEO pleads guilty in federal Suboxone probe a day after stepping down from post

Former Indivior CEO pleads guilty in federal Suboxone probe a day after stepping down from post

Fierce Pharma

Flag link:

Tiny Trevena returns to FDA in second bid for controversial opioid painkiller

Tiny Trevena returns to FDA in second bid for controversial opioid painkiller

Endpoints

Flag link:

FDA starts review of Pfizer, Lilly’s non-opioid painkiller

FDA starts review of Pfizer, Lilly’s non-opioid painkiller

Pharmaforum

non-opioid pain treatments

Flag link:

Baudax Bio Wins FDA Approval for Anjeso, a Non-Opioid Pain Treatment

Baudax Bio Wins FDA Approval for Anjeso, a Non-Opioid Pain Treatment

BioSpace

Flag link:

Vertex drops VX-961 to continue search for perfect pain drug

Vertex drops VX-961 to continue search for perfect pain drug

Fierce Biotech

Vertex Pharmaceuticals

Flag link:

FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug

FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug

BioSpace

Durect Corporation

non-opioid pain treatments

Flag link:

Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee

Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee

Motley Fool

Nektar Therapeutics

Flag link:

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Fierce Pharma

Flag link:

IPO take 2: Kindler's Centrexion restarts bid to fund pain trial

IPO take 2: Kindler's Centrexion restarts bid to fund pain trial

Fierce Biotech

clinical trials

osteoarthritis of the knee

Flag link:

Pages